Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efaproxiral with Chemoradiation in Stage III NSCLC
NCT00055887Phase 3Withdrawn
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Nov 2002
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of efaproxiral in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Overall Survival. Planned start Nov 2002; status: withdrawn.
02
Drugs
efaproxiral
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00055887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055887.